Clinical Trial Update: Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating QBW251 in bronchiectasis was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis

Drugs mentioned

• QBW251

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Bronchiectasis | Phase 2 | Status: TERMINATED | Results posted: 2025-03-06